These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20015633)

  • 1. Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.
    Saito Y; Yasunaga M; Kuroda J; Koga Y; Matsumura Y
    Eur J Cancer; 2010 Feb; 46(3):650-8. PubMed ID: 20015633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
    Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
    Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor.
    Saito Y; Yasunaga M; Kuroda J; Koga Y; Matsumura Y
    Cancer Sci; 2008 Jun; 99(6):1258-64. PubMed ID: 18429960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
    Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
    Kenmotsu H; Yasunaga M; Goto K; Nagano T; Kuroda J; Koga Y; Takahashi A; Nishiwaki Y; Matsumura Y
    Cancer; 2010 Oct; 116(19):4597-604. PubMed ID: 20572031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.
    Takahashi A; Ohkohchi N; Yasunaga M; Kuroda J; Koga Y; Kenmotsu H; Kinoshita T; Matsumura Y
    Clin Cancer Res; 2010 Oct; 16(19):4822-31. PubMed ID: 20807756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Saito Y; Matsumura Y
    Int J Cancer; 2009 Jun; 124(11):2505-11. PubMed ID: 19189401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
    Koizumi F; Kitagawa M; Negishi T; Onda T; Matsumoto S; Hamaguchi T; Matsumura Y
    Cancer Res; 2006 Oct; 66(20):10048-56. PubMed ID: 17047068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
    Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
    Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.
    Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
    Clin Cancer Res; 2009 Jul; 15(13):4348-55. PubMed ID: 19509138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
    Burris HA; Infante JR; Anthony Greco F; Thompson DS; Barton JH; Bendell JC; Nambu Y; Watanabe N; Jones SF
    Cancer Chemother Pharmacol; 2016 May; 77(5):1079-86. PubMed ID: 27061418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.
    Matsumura Y
    Adv Drug Deliv Rev; 2011 Mar; 63(3):184-92. PubMed ID: 20561951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression.
    Sumitomo M; Koizumi F; Asano T; Horiguchi A; Ito K; Asano T; Kakizoe T; Hayakawa M; Matsumura Y
    Cancer Res; 2008 Mar; 68(6):1631-5. PubMed ID: 18339841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model.
    Miyazaki O; Sekine K; Nakajima N; Ichimura E; Ebara K; Nagai D; Onda T; Miyakawa Y; Okamoto K; Morino T
    Int J Cancer; 2014 Jan; 134(1):218-23. PubMed ID: 23775066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.
    Zhang R; Saito R; Mano Y; Sumiyoshi A; Kanamori M; Sonoda Y; Kawashima R; Tominaga T
    Drug Deliv; 2016 Oct; 23(8):2780-2786. PubMed ID: 26330269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
    Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
    Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.